Last 5 Days to Apply: Shape the Future with DES Pune University
New Delhi [India], June 25: The clock is ticking for aspiring innovators and future leaders, DES Pune University (DES PU) announces the final five days to apply for Round 2 Undergraduate (UG) Admissions, which close on June 30, 2025. As one of India's most respected institutions, DES Pune University (DES PU) invites driven students to be part of a transformative educational journey deeply rooted in a 140-year legacy of academic excellence and propelled by cutting-edge research and innovation.
A Legacy of Vision, A Future of Innovation
Deccan Education Society (DES), established in 1884, is a prestigious institution with over 140 years of legacy in advancing Indian education. It has founded more than 45 respected institutions, including Fergusson College, BMCC, and Willingdon College. DES has produced a distinguished alumni network of leaders, reformers, scientists, and cultural icons who have significantly contributed to India's development and global presence.
Established by the historic Deccan Education Society, DES Pune University (DES PU) embodies over a century of commitment to nation-building through education. Today, DES Pune University (DES PU) is a dynamic, future-forward university that merges this rich legacy with a mission to nurture creativity, global competence, and research excellence.
From founding minds who contributed to India's intellectual independence to today's leaders of industry and academia, DES Pune University (DES PU) continues to be a launchpad for greatness.
'Our university is more than a campus--it's a movement. We offer students an ecosystem where legacy meets innovation, and dreams find purpose.' -- Prof. Nitin M. Kulkarni, Officiating Vice Chancellor, DES Pune University (DES PU).
Programmes That Prepare You for the Real World
DES Pune University (DES PU) offers a broad portfolio of Undergraduate Programme, including:
- B.Tech. in emerging tech fields
- B.Sc. and B.A. in Sciences and Humanities
- BBA and B.Des. to shape the next generation of business and design thinkers
Each Programme is designed to balance theoretical rigor with practical exposure, ensuring that students graduate not just with degrees--but with direction.
Through internships, hands-on workshops, and deep industry engagement, DES Pune University (DES PU) equips students to excel in a competitive job market and as future entrepreneurs.
Eligibility Criteria
DES Pune University (DES PU) maintains a fair, transparent, and inclusive admission process designed to identify well-rounded candidates with strong academic potential and leadership qualities.
Academic Qualification Criteria:
Minimum 50% aggregate marks in 10+2 or equivalent examination from a recognized board (at least 45% marks for candidates belonging to the Reserved Category from Maharashtra State only).
Accepted Entrance Examinations:
Depending on the Programme, applicants must present scores from one of the following recognized entrance tests, or appear for the DES PU Common Entrance Test (UCET) if other scores are not available:
- B.Tech. - JEE Main / MHT CET / PERA CET / DES PU UCET
- BBA / BCA - MAH BBA/BCA CET / PERA CET / DES PU UCET
- B.Des. - UCEED / NIFT / NATA / NID / PERA CET / DES PU UCET
- Other Programmes (B.Sc., B.A., etc.) - Any relevant state-level entrance exam or DES PU UCET
Start Your Application - Build Your Future at DES Pune University (DES PU)
With the approaching Round 2 deadline, it is an opportune moment to proceed
- Last Date to Apply: June 30, 2025
- Apply Online: https://despu.edu.in
- 10% scholarship on first-year tuition fees for DES Alumni applying to any programme
Seats are limited, and competition is high--early applicants stand a greater chance at Programme placement, and co-curricular opportunities.
Be Part of the Legacy
Whether you're an aspiring engineer, designer, researcher, or entrepreneur, DES Pune University (DES PU) welcomes you to join a community that has educated changemakers for over a century. At DES Pune University (DES PU), tradition meets transformation--and your journey begins now.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by SMPL. ANI will not be responsible in any way for the content of the same)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
P B Balaji, a CFO who plays with a straight bat, now captains JLR
Balaji's rise to the top spot at JLR as its CEO comes at a time when the company is in a transition phase, lining up plans for more electric vehicles Shine Jacob Chennai Listen to This Article His career moves across the world — from countries like Switzerland and Singapore to cities like London — meant his daughter had to switch nine schools in just 15 years. This is just one glimpse into the lesser-known personal side of the otherwise career-oriented Pathamadai Balachandran Balaji, who was elevated as the first Indian chief executive officer of Tata Motors-owned luxury carmaker Jaguar Land Rover (JLR) on Monday. However, his life is about more than just boardroom talks and business growth. Balaji, in his mid-50s, is a die-hard cricket enthusiast and an admirer of Virat Kohli, yet chooses not to
